# La société Synapse Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/la-societe-synapse-medicine

- Industry: Software
- Headquarters: Bordeaux, France
- Website: www.synapse-medicine.com
- Total disclosed funding: $1.5M
- Latest round: Series A (Feb 15, 2019)
- Investors on record: 4

## About

La société Synapse Medicine develops advanced clinical decision support software aimed at enhancing medication management in healthcare systems, thereby improving patient safety and streamlining workflows for healthcare professionals.La société Synapse Medicine, founded in 2017 in Bordeaux, France, specializes in clinical decision support software. The company was founded by Alicia Bel-Létoile, Clement Goehrs, and Louis Létinier. Clement Goehrs serves as the CEO. La société Synapse Medicine has completed 3 deals, with the most recent funding round occurring on March 1, 2022, when it raised EUR 25 million. The funding was led by Korelya Capital, with participation from BNP Paribas Développement, MACSF, Mutuelles Impact, and XAnge. The company operates out of its headquarters in Bordeaux and has plans for further expansion.Synapse Medicine specializes in developing clinical decision support software that enhances medication management within healthcare systems. Their core offerings include drug information monographs, patient clinical profiling for personalized prescriptions, and advanced prescribing tools that facilitate streamlined order entries and automated data importation for treatment entries. The platform includes a robust drug interaction analysis system and clinical alerts for contraindications, especially for elderly patients. Their products cater to a diverse clientele, including healthcare providers, pharmacies, and medical software developers in various regions, notably the United States and Europe. By integrating their React Native components into electronic health records (EHR) and e-prescribing software, Synapse Medicine aims to reduce workloads for healthcare providers while improving patient safety.In 2022, Synapse Medicine reported a revenue of EUR 915,006.2 and an EBITDA of EUR -6,965,953.2. The company generates revenue through B2B partnerships and subscriptions with healthcare organizations and software developers, facilitating seamless integration of their clinical decision support technology into existing workflows. Clients typically engage in licensing agreements for access to Synapse Medicine's tools, including their Reliable Drug Information database and automated prescribing analysis features, structured to meet various client needs.In March 2022, La société Synapse Medicine raised EUR 25 million in venture funding led by Korelya Capital. The company plans to use this funding to support its expansion into North America, with a new office set to open in New York City. This strategic move aims to enhance their market presence and better serve healthcare providers in the region. Specific new products are being developed to further improve clinical decision support capabilities, aligning with their goal of enhancing healthcare outcomes.

## Funding rounds

- Series A, Feb 15, 2019, $1.5M — XAnge, Kima Ventures, Avrhm Capital, BNP Paribas Developpement

## Investors

- XAnge (https://capitalatlas.ai/funds/xange) — Series A
- Kima Ventures (https://capitalatlas.ai/funds/kima-ventures) — Series A
- Avrhm Capital — Series A
- BNP Paribas Developpement (https://capitalatlas.ai/funds/bnp-paribas-developpement) — Series A